MAX Chat
Company Analysis Bluebird Bio
1. Summary
Advantages
- Price (4.97 $) is less than fair price (10.55 $)
Disadvantages
- Dividends (0%) are below the sector average (0.527%).
- The stock's return over the last year (-60.57%) is lower than the sector average (-1.85%).
- Current debt level 77.84% has increased over 5 years from 11.04%.
- The company's current efficiency (ROE=-295.35%) is lower than the sector average (ROE=14.17%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Bluebird Bio | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | 8.6% | 1.2% |
| 90 days | 2.5% | 4.9% | 21.7% |
| 1 year | -60.6% | -1.8% | 21.8% |
BLUE vs Sector: Bluebird Bio has significantly underperformed the "Healthcare" sector by -58.72% over the past year.
BLUE vs Market: Bluebird Bio has significantly underperformed the market by -82.33% over the past year.
Stable price: BLUE is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: BLUE with weekly volatility of -1.16% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (4.97 $) is lower than the fair price (10.55 $).
Price significantly below the fair price: The current price (4.97 $) is 112.3% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (64.15).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (90.03).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (-2.42) is lower than that of the sector as a whole (18.96).
P/BV vs Market: The company's P/BV (-2.42) is lower than that of the market as a whole (9.39).
4.4. P/S
P/S vs Sector: The company's P/S indicator (0.9087) is lower than that of the sector as a whole (32.77).
P/S vs Market: The company's P/S indicator (0.9087) is lower than that of the market as a whole (10.12).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-2.37) is lower than that of the sector as a whole (274.79).
EV/Ebitda vs Market: The company's EV/Ebitda (-2.37) is lower than that of the market as a whole (50.91).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -12.22% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-12.22%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).
5.4. ROE
ROE vs Sector: The company's ROE (-295.35%) is lower than that of the sector as a whole (14.17%).
ROE vs Market: The company's ROE (-295.35%) is lower than that of the market as a whole (11.64%).
5.5. ROA
ROA vs Sector: The company's ROA (-44.6%) is lower than that of the sector as a whole (1.18%).
ROA vs Market: The company's ROA (-44.6%) is lower than that of the market as a whole (6.89%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-82.72%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-82.72%) is lower than that of the market as a whole (11.08%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.527%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
